177 related articles for article (PubMed ID: 32584958)
1. Understanding Early and Late Endpoints in Registrational Trials of Community-acquired Bacterial Pneumonia.
Talbot GH
Clin Infect Dis; 2021 Nov; 73(9):e2613-e2615. PubMed ID: 32584958
[No Abstract] [Full Text] [Related]
2. Progress on developing endpoints for registrational clinical trials of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections: update from the Biomarkers Consortium of the Foundation for the National Institutes of Health.
Talbot GH; Powers JH; Fleming TR; Siuciak JA; Bradley J; Boucher H;
Clin Infect Dis; 2012 Oct; 55(8):1114-21. PubMed ID: 22744885
[TBL] [Abstract][Full Text] [Related]
3. Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
Lodise TP; Low DE
Drugs; 2012 Jul; 72(11):1473-93. PubMed ID: 22779432
[TBL] [Abstract][Full Text] [Related]
4. Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia.
Zhanel GG; Deng C; Zelenitsky S; Lawrence CK; Adam HJ; Golden A; Berry L; Schweizer F; Zhanel MA; Irfan N; Bay D; Lagacé-Wiens P; Walkty A; Mandell L; Lynch JP; Karlowsky JA
Drugs; 2021 Feb; 81(2):233-256. PubMed ID: 33247830
[TBL] [Abstract][Full Text] [Related]
5. Ceftaroline fosamil as first-line versus second-line treatment for acute bacterial skin and skin structure infections (ABSSSI) or community-acquired bacterial pneumonia (CABP).
Guervil DJ; Kaye KS; Hassoun A; Cole P; Huang XY; Friedland HD
J Chemother; 2016 Jun; 28(3):180-6. PubMed ID: 25817579
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of omadacycline for treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections in patients with mild-to-moderate renal impairment.
Cornely OA; File TM; Garrity-Ryan L; Chitra S; Noble R; McGovern PC
Int J Antimicrob Agents; 2021 Feb; 57(2):106263. PubMed ID: 33326848
[TBL] [Abstract][Full Text] [Related]
7. Omadacycline Oral Dosing and Pharmacokinetics in Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infection.
Leviton IM; Amodio-Groton M
Clin Drug Investig; 2022 Mar; 42(3):193-197. PubMed ID: 35192150
[TBL] [Abstract][Full Text] [Related]
8. Concordance of Early and Late End Points for Community-acquired Bacterial Pneumonia Trials.
Bart SM; Nambiar S; Gopinath R; Rubin D; Farley JJ
Clin Infect Dis; 2021 Nov; 73(9):e2607-e2612. PubMed ID: 32584969
[TBL] [Abstract][Full Text] [Related]
9. Ceftaroline fosamil for treating skin and skin structure infections or community-acquired pneumonia in patients with renal insufficiency.
Maggiore C; Pasquale T; Cole P; Friedland HD
Expert Rev Clin Pharmacol; 2015 Jan; 8(1):141-53. PubMed ID: 25467425
[TBL] [Abstract][Full Text] [Related]
10. Real-world effectiveness of omadacycline and impact of unapproved omadacycline prescription claims among adult outpatients with community-acquired bacterial pneumonia or acute bacterial skin and skin structure infections.
Lodise TP; Gunter K; Mu F; Gao E; Yang D; Yim E; Sandor S; Berman G
J Manag Care Spec Pharm; 2023 Aug; 29(8):952-964. PubMed ID: 37307087
[No Abstract] [Full Text] [Related]
11. Ceftaroline fosamil for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection.
Casapao AM; Steed ME; Levine DP; Rybak MJ
Expert Opin Pharmacother; 2012 Jun; 13(8):1177-86. PubMed ID: 22594846
[TBL] [Abstract][Full Text] [Related]
12. An update for community-acquired bacterial pneumonia pharmacotherapy: what's new and where does it fit?
DeBellis HF; Jones MC; Kincaid SE
J Pharm Pract; 2012 Dec; 25(6):569-75. PubMed ID: 23065389
[TBL] [Abstract][Full Text] [Related]
13. Spotlight on solithromycin in the treatment of community-acquired bacterial pneumonia: design, development, and potential place in therapy.
Donald BJ; Surani S; Deol HS; Mbadugha UJ; Udeani G
Drug Des Devel Ther; 2017; 11():3559-3566. PubMed ID: 29263651
[TBL] [Abstract][Full Text] [Related]
14. Lefamulin: a promising new pleuromutilin antibiotic in the pipeline.
Dillon C; Guarascio AJ; Covvey JR
Expert Rev Anti Infect Ther; 2019 Jan; 17(1):5-15. PubMed ID: 30513017
[TBL] [Abstract][Full Text] [Related]
15. SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia.
File TM; Rewerska B; Vucinic-Mihailovic V; Gonong JRV; Das AF; Keedy K; Taylor D; Sheets A; Fernandes P; Oldach D; Jamieson BD
Clin Infect Dis; 2016 Oct; 63(8):1007-1016. PubMed ID: 27448679
[TBL] [Abstract][Full Text] [Related]
16. Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent.
Zhanel GG; Esquivel J; Zelenitsky S; Lawrence CK; Adam HJ; Golden A; Hink R; Berry L; Schweizer F; Zhanel MA; Bay D; Lagacé-Wiens PRS; Walkty AJ; Lynch JP; Karlowsky JA
Drugs; 2020 Feb; 80(3):285-313. PubMed ID: 31970713
[TBL] [Abstract][Full Text] [Related]
17. Antimicrobial activity of the pleuromutilin antibiotic BC-3781 against bacterial pathogens isolated in the SENTRY antimicrobial surveillance program in 2010.
Paukner S; Sader HS; Ivezic-Schoenfeld Z; Jones RN
Antimicrob Agents Chemother; 2013 Sep; 57(9):4489-95. PubMed ID: 23836172
[TBL] [Abstract][Full Text] [Related]
18. A collaborative model for endpoint development for acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia.
Toerner JG; Burke L; Komo S; Papadopoulos E
Clin Infect Dis; 2012 Oct; 55(8):1122-3. PubMed ID: 22744886
[No Abstract] [Full Text] [Related]
19. Population PK Modeling and Target Attainment Simulations to Support Dosing of Ceftaroline Fosamil in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infections and Community-Acquired Bacterial Pneumonia.
Riccobene TA; Khariton T; Knebel W; Das S; Li J; Jandourek A; Carrothers TJ; Bradley JS
J Clin Pharmacol; 2017 Mar; 57(3):345-355. PubMed ID: 27510635
[TBL] [Abstract][Full Text] [Related]
20. Lefamulin: A Novel Semisynthetic Pleuromutilin Antibiotic for Community-acquired Bacterial Pneumonia.
Watkins RR; File TM
Clin Infect Dis; 2020 Dec; 71(10):2757-2762. PubMed ID: 32221520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
